Clinical Trials
389
52 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
34
8.7%
Completed
268
68.9%
Enrolling By Invitation
10
2.6%
No Longer Available
1
0.3%
Not yet recruiting
8
2.1%
Recruiting
23
5.9%
Suspended
2
0.5%
Terminated
10
2.6%
Unknown
11
2.8%
Withdrawn
22
5.7%
No approval data available
- Cassandra Barksdale, 43, alleges a pathology specimen labeling error at Kaiser Permanente led to a false endometrial cancer diagnosis and an unneeded full hysterectomy on May 15, 2025. - A September DNA analysis reportedly revealed the aggressive endometrial uterine cancer tissue sample belonged to a different patient, not Barksdale. - Barksdale and her attorneys filed a lawsuit against Kaiser Permanente seeking unspecified damages for months of physical and emotional pain. - Kaiser Permanente acknowledged the incident, stating it took immediate steps to prevent recurrence and is committed to resolving the matter fairly.
- A $3.3 million five-year NIH grant will fund a study tracking approximately 4,000 diverse older adults to examine how cultural differences shape subjective cognitive decline (SCD) reporting. - The research aims to determine whether specific types of cognitive complaints—such as memory deficits versus executive function difficulties—predict distinct underlying pathologies like Alzheimer's disease or cerebrovascular disease. - The study addresses critical gaps in SCD research, including lack of racial and socioeconomic diversity, absence of longitudinal data, and the confounding overlap between SCD and depression. - Findings could help clinicians identify which subjective complaints represent genuine red flags for future dementia up to 5 to 10 years before objective cognitive testing detects deficits.
- A randomized trial found medically tailored meals plus lifestyle counseling lowered HbA1c significantly more than monthly food subsidies at 6 months (7.74% vs. 8.17%, P = .037). - The meal intervention also improved systolic blood pressure, reduced food insecurity, and enhanced diet quality and self-efficacy compared to subsidies. - A separate Kaiser Permanente study showed weekly healthy grocery deliveries improved blood sugar by nearly half a point over 6 months in Medicaid patients with diabetes. - Benefits from both nutritional interventions did not persist 6 months after the programs ended, suggesting the need for sustained support.
- AI is forcing medical schools to rapidly reconsider physician training, with educators describing this as a "key inflection point for medical education," according to NYU's Marc Triola. - New AI tools enable personalized assessment of trainees' communication and clinical reasoning skills, areas that have long been difficult to evaluate directly. - Concerns about "never-skilling" and "deskilling" arise as trainees offload cognitive tasks to AI, though some experts argue not all deskilling is harmful and may free capacity for essential skills. - Medical education leaders emphasize the need for adaptive training models that partner with learners, as the evidence base on AI's educational effects remains surprisingly limited.
- SonoMotion has received FDA 510(k) clearance for its Break Wave device, which uses low-pressure focused ultrasound to fragment kidney stones without requiring anesthesia or dietary restrictions. - The non-invasive system employs standing stress waves guided by real-time ultrasound imaging and can be performed in any healthcare setting with patients fully awake. - Break Wave works alongside Stone Clear, which received FDA de novo clearance in October 2024, to provide a complete anesthesia-free treatment pathway for kidney stone management. - The technology offers immediate treatment options for patients with symptomatic obstructing ureteral stones, potentially eliminating weeks of pain while waiting for stones to pass naturally.
- A clinical study published in Neurology Journal demonstrated that extending rituximab dosing intervals from every 6 months to every 12 months maintained high effectiveness in relapsing multiple sclerosis patients without increasing disease activity risk. - The research found that over 95% of patients achieved stability after one year of treatment, with both dosing schedules showing minimal disease activity, relapses, and disability progression over five years of follow-up. - Extended dosing intervals reduce infection risk and immune suppression while maintaining disease control, potentially making rituximab a viable "forever therapy" for multiple sclerosis patients. - The study used target trial design methodology with thousands of patients to demonstrate that once-yearly, low-dose rituximab can be as effective as more frequent dosing regimens.
- The CAVIAR trial demonstrated that alirocumab combined with rosuvastatin safely reduced LDL cholesterol levels by more than 50% in heart transplant patients within one year. - Despite significant cholesterol reduction, the study did not show meaningful differences in coronary plaque progression between treatment groups. - The findings support PCSK9 inhibitor use for cholesterol management in transplant patients, though longer-term studies are needed to assess impact on cardiac allograft vasculopathy prevention. - Both treatment regimens were well-tolerated with no significant adverse events reported in the 114-patient randomized controlled trial.
- Abridge raised $300 million in Series E funding led by Andreessen Horowitz, bringing its valuation to $5.3 billion for its ambient listening technology that automates clinical documentation. - The AI-powered platform serves over 150 health systems including Kaiser Permanente, UPMC, and Sutter Health, generating clinical notes from medical conversations across 55 specialties and 28 languages. - The company reports significant clinical impact with 60-70% reduction in burnout and over 90% clinician retention rate, while projecting support for more than 50 million medical conversations in 2025. - This funding round follows a $250 million raise in February, representing one of the most substantial health tech deals of 2024 as AI scribes gain rapid adoption to address clinician burnout.
- Kaiser Permanente Southern California will launch an FDA-approved gene therapy program for pediatric sickle cell disease patients through a partnership with Downey Medical Center and City of Hope. - The program will serve approximately 220 children aged 12 and above currently treated by Kaiser Permanente, with the first patient scheduled for treatment this summer. - The gene therapy process involves extracting stem cells from the patient's blood, modifying them in a laboratory, and reinfusing them to provide a cure without requiring donor matching. - This treatment addresses a critical unmet need, as sickle cell disease affects approximately 100,000 Americans and reduces life expectancy by more than 20 years compared to the national average.
- New research from Kaiser Permanente shows autism diagnoses increased by 175% between 2011 and 2022, with the latest CDC data indicating 1 in 31 U.S. children are now affected. - Young adults aged 26-34 experienced the most dramatic rise with a 450% increase in diagnoses, highlighting growing recognition of autism spectrum disorders across age groups. - While boys remain four times more likely to be diagnosed with autism than girls, the gender gap is narrowing as diagnoses among girls rose by 305% compared to 185% for boys during the study period.
